BACKGROUND: Soluble urokinase plasminogen activator receptor (suPAR) has been studied in a variety of diseases. The aim of the study is to investigate the levels of suPAR in neonates with sepsis. METHODS: The infants enrolled to this prospective study were classified into four groups. Group 1, 2, and 3 were referred as the patient groups (40 infants), and group 4 was referred as control group (26 infants). Blood samples for whole blood count, C-reactive protein (CRP), suPAR and blood culture were obtained before initiating antimicrobial therapy, and two further samples were obtained on day 3 and at the end of the treatment for CRP and suPAR. RESULTS: The mean gestational ages of patient and control groups was similar. The median level of initial suPAR was 18.8 ng/mL (range 6.8-30.1 ng/mL) in the patient groups, and 6.0 ng/mL (range 3.7-10.8 ng/mL) in the control group (P < 0.001). A significant decrease in suPAR level was observed from the inclusion to the third day and end of the treatment (P < 0.001). The area under the curve (AUC) for suPAR is 0.959 (95% Cl: 0.919-0.999) and for CRP is 0.782 (95% Cl: 0.669-0.895). At a cut-off value of 11.3 ng/mL for suPAR the specificity was 100%, and the sensitivity was 82.5%. There was a positive correlation between laboratory values of CRP and suPAR (r: 0.359, P = 0.003). CONCLUSION: This is the first study that investigated the levels of suPAR in neonates and our results demonstrate that suPAR is a powerful marker of inflammation in infants with sepsis.
BACKGROUND: Soluble urokinase plasminogen activator receptor (suPAR) has been studied in a variety of diseases. The aim of the study is to investigate the levels of suPAR in neonates with sepsis. METHODS: The infants enrolled to this prospective study were classified into four groups. Group 1, 2, and 3 were referred as the patient groups (40 infants), and group 4 was referred as control group (26 infants). Blood samples for whole blood count, C-reactive protein (CRP), suPAR and blood culture were obtained before initiating antimicrobial therapy, and two further samples were obtained on day 3 and at the end of the treatment for CRP and suPAR. RESULTS: The mean gestational ages of patient and control groups was similar. The median level of initial suPAR was 18.8 ng/mL (range 6.8-30.1 ng/mL) in the patient groups, and 6.0 ng/mL (range 3.7-10.8 ng/mL) in the control group (P < 0.001). A significant decrease in suPAR level was observed from the inclusion to the third day and end of the treatment (P < 0.001). The area under the curve (AUC) for suPAR is 0.959 (95% Cl: 0.919-0.999) and for CRP is 0.782 (95% Cl: 0.669-0.895). At a cut-off value of 11.3 ng/mL for suPAR the specificity was 100%, and the sensitivity was 82.5%. There was a positive correlation between laboratory values of CRP and suPAR (r: 0.359, P = 0.003). CONCLUSION: This is the first study that investigated the levels of suPAR in neonates and our results demonstrate that suPAR is a powerful marker of inflammation in infants with sepsis.
Authors: C F Sier; R Stephens; J Bizik; A Mariani; M Bassan; N Pedersen; L Frigerio; A Ferrari; K Danø; N Brünner; F Blasi Journal: Cancer Res Date: 1998-05-01 Impact factor: 12.701
Authors: R W Stephens; H J Nielsen; I J Christensen; O Thorlacius-Ussing; S Sørensen; K Danø; N Brünner Journal: J Natl Cancer Inst Date: 1999-05-19 Impact factor: 13.506
Authors: P Wittenhagen; G Kronborg; N Weis; H Nielsen; N Obel; S S Pedersen; J Eugen-Olsen Journal: Clin Microbiol Infect Date: 2004-05 Impact factor: 8.067
Authors: Sisse R Ostrowski; Terese L Katzenstein; Timo Piironen; Jan Gerstoft; Bente K Pedersen; Henrik Ullum Journal: J Acquir Immune Defic Syndr Date: 2004-04-01 Impact factor: 3.731
Authors: Alexander Koch; Sebastian Voigt; Carsten Kruschinski; Edouard Sanson; Hanna Dückers; Andreas Horn; Eray Yagmur; Henning Zimmermann; Christian Trautwein; Frank Tacke Journal: Crit Care Date: 2011-02-16 Impact factor: 9.097
Authors: Kristian Kofoed; Ove Andersen; Gitte Kronborg; Michael Tvede; Janne Petersen; Jesper Eugen-Olsen; Klaus Larsen Journal: Crit Care Date: 2007 Impact factor: 9.097